Group,Skill,Individual,ORCID,Affiliation
Drug Discovery Group,Medicinal chemistry,Yojana Gadiya,https://orcid.org/0000-0002-7683-0452,Fraunhofer-Gesellschaft
Drug Discovery Group,Target identification,Yojana Gadiya,https://orcid.org/0000-0002-7683-0452,Fraunhofer-Gesellschaft
Drug Discovery Group,Biological discovery,Yojana Gadiya,https://orcid.org/0000-0002-7683-0452,Fraunhofer-Gesellschaft
Drug Discovery Group,Mechanism of action (MoA),Yojana Gadiya,https://orcid.org/0000-0002-7683-0452,Fraunhofer-Gesellschaft
Drug Discovery Group,Medicinal chemistry,Johanna Huchting,https://orcid.org/0000-0001-6368-3273,Fraunhofer-Gesellschaft
Drug Discovery Group,High-throughput screening (HTS),Johanna Huchting,https://orcid.org/0000-0001-6368-3273,Fraunhofer-Gesellschaft
Drug Discovery Group,Hit confirmation | hit validation,Johanna Huchting,https://orcid.org/0000-0001-6368-3273,Fraunhofer-Gesellschaft
Drug Discovery Group,Pro-drugs,Johanna Huchting,https://orcid.org/0000-0001-6368-3273,Fraunhofer-Gesellschaft
Drug Development Group,Data management,Philip Gribbon,https://orcid.org/0000-0001-7655-2459,Fraunhofer-Gesellschaft
Communication and Project Management Group,Project management,Philip Gribbon,https://orcid.org/0000-0001-7655-2459,Fraunhofer-Gesellschaft
Drug Discovery Group,Target identification,Philip Gribbon,https://orcid.org/0000-0001-7655-2459,Fraunhofer-Gesellschaft
Drug Discovery Group,Natural products,Philip Gribbon,https://orcid.org/0000-0001-7655-2459,Fraunhofer-Gesellschaft
Drug Discovery Group,High-throughput screening (HTS),Philip Gribbon,https://orcid.org/0000-0001-7655-2459,Fraunhofer-Gesellschaft
Drug Discovery Group,Hit-to-lead (HTL) | lead generation,Philip Gribbon,https://orcid.org/0000-0001-7655-2459,Fraunhofer-Gesellschaft
Drug Discovery Group,In-vivo toxicity testing,Philip Gribbon,https://orcid.org/0000-0001-7655-2459,Fraunhofer-Gesellschaft
Drug Discovery Group,Mechanism of action (MoA),Philip Gribbon,https://orcid.org/0000-0001-7655-2459,Fraunhofer-Gesellschaft
Drug Discovery Group,Hit confirmation | hit validation,Philip Gribbon,https://orcid.org/0000-0001-7655-2459,Fraunhofer-Gesellschaft
Drug Discovery Group,Target validation,Philip Gribbon,https://orcid.org/0000-0001-7655-2459,Fraunhofer-Gesellschaft
Drug Development Group,Clinical statistics,Ziaurrehman Tanoli, https://orcid.org/0000-0003-2435-9862,University of Helsinki (FIMM-UH)
Drug Discovery Group,Medicinal chemistry,Ziaurrehman Tanoli, https://orcid.org/0000-0003-2435-9862,University of Helsinki (FIMM-UH)
Drug Discovery Group,Pharmacodynamics (PD),Ziaurrehman Tanoli, https://orcid.org/0000-0003-2435-9862,University of Helsinki (FIMM-UH)
Drug Discovery Group,Pharmacokinetics (PK),Ziaurrehman Tanoli, https://orcid.org/0000-0003-2435-9862,University of Helsinki (FIMM-UH)
Drug Discovery Group,Target identification,Ziaurrehman Tanoli, https://orcid.org/0000-0003-2435-9862,University of Helsinki (FIMM-UH)
Drug Discovery Group,Mechanism of action (MoA),Ziaurrehman Tanoli, https://orcid.org/0000-0003-2435-9862,University of Helsinki (FIMM-UH)
Communication and Project Management Group,Project management,Markus Vähä-Koskela, https://orcid.org/0000-0001-7764-7820,University of Helsinki (FIMM-UH)
Drug Discovery Group,Biological discovery,Markus Vähä-Koskela, https://orcid.org/0000-0001-7764-7820,University of Helsinki (FIMM-UH)
Drug Discovery Group,High-throughput screening (HTS),Markus Vähä-Koskela, https://orcid.org/0000-0001-7764-7820,University of Helsinki (FIMM-UH)
Communication and Project Management Group,Project communication and dissemination,Jordi Carreras-Puigvert, https://orcid.org/0000-0002-7671-3707,Uppsala Universitet
Communication and Project Management Group,Project management,Jordi Carreras-Puigvert, https://orcid.org/0000-0002-7671-3707,Uppsala Universitet
Drug Discovery Group,Target identification,Jordi Carreras-Puigvert, https://orcid.org/0000-0002-7671-3707,Uppsala Universitet
Drug Discovery Group,High-throughput screening (HTS),Jordi Carreras-Puigvert, https://orcid.org/0000-0002-7671-3707,Uppsala Universitet
Drug Discovery Group,Mechanism of action (MoA),Jordi Carreras-Puigvert, https://orcid.org/0000-0002-7671-3707,Uppsala Universitet
Drug Discovery Group,Drug combinations,Jordi Carreras-Puigvert, https://orcid.org/0000-0002-7671-3707,Uppsala Universitet
Drug Discovery Group,Hit confirmation | hit validation,Jordi Carreras-Puigvert, https://orcid.org/0000-0002-7671-3707,Uppsala Universitet
Drug Discovery Group,Target validation,Jordi Carreras-Puigvert, https://orcid.org/0000-0002-7671-3707,Uppsala Universitet
Drug Development Group,Pre-clinical pharmacology,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Development Group,Active pharmaceutical ingredient (API) manufacturing,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Development Group,Phase 2 trials,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Development Group,Phase 1 trials,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Development Group,Investigational new drug (IND) submission,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Development Group,Clinical study design,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Development Group,Adaptive trial design,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Communication and Project Management Group,Legal expertise,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Discovery Group,Medicinal chemistry,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Discovery Group,Pharmacodynamics (PD),Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Discovery Group,Pharmacokinetics (PK),Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Discovery Group,Drug delivery,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Discovery Group,Drug Formulation,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Discovery Group,In-vivo modelling,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Discovery Group,Hit-to-lead (HTL) | lead generation,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Discovery Group,In-vivo toxicity testing,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Discovery Group,Mechanism of action (MoA),Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Discovery Group,Drug combinations,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Discovery Group,In-vivo efficacy evaluation,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Discovery Group,Absorption distribution metabolism elimination (ADME),Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Discovery Group,Target validation,Martin de Kort, https://orcid.org/0000-0002-7264-5436,EATRIS
Drug Development Group,Pre-clinical pharmacology,Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Development Group,Active pharmaceutical ingredient (API) manufacturing,Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Development Group,Clinical statistics,Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Development Group,Data management,Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Communication and Project Management Group,Project management,Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Discovery Group,Medicinal chemistry,Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Discovery Group,Pharmacodynamics (PD),Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Discovery Group,Pharmacokinetics (PK),Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Discovery Group,Target identification,Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Discovery Group,Natural products,Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Discovery Group,High-throughput screening (HTS),Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Discovery Group,Hit-to-lead (HTL) | lead generation,Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Discovery Group,Mechanism of action (MoA),Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Discovery Group,Drug combinations,Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Discovery Group,Hit confirmation | hit validation,Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Discovery Group,Pro-drugs,Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Discovery Group,Absorption distribution metabolism elimination (ADME),Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Discovery Group,Target validation,Andrea Zaliani,https://orcid.org/0000-0002-1740-8390,Fraunhofer-Gesellschaft
Drug Development Group,Pre-clinical pharmacology,Brinton Seashore-Ludlow,https://orcid.org/0000-0001-8658-5967,Karolinska Institutet
Communication and Project Management Group,Project management,Brinton Seashore-Ludlow,https://orcid.org/0000-0001-8658-5967,Karolinska Institutet
Drug Discovery Group,Target identification,Brinton Seashore-Ludlow,https://orcid.org/0000-0001-8658-5967,Karolinska Institutet
Drug Discovery Group,Biological discovery,Brinton Seashore-Ludlow,https://orcid.org/0000-0001-8658-5967,Karolinska Institutet
Drug Discovery Group,High-throughput screening (HTS),Brinton Seashore-Ludlow,https://orcid.org/0000-0001-8658-5967,Karolinska Institutet
Drug Discovery Group,Mechanism of action (MoA),Brinton Seashore-Ludlow,https://orcid.org/0000-0001-8658-5967,Karolinska Institutet
Drug Discovery Group,Drug combinations,Brinton Seashore-Ludlow,https://orcid.org/0000-0001-8658-5967,Karolinska Institutet
Drug Discovery Group,Hit confirmation | hit validation,Brinton Seashore-Ludlow,https://orcid.org/0000-0001-8658-5967,Karolinska Institutet
Drug Development Group,Phase 3 trials,Saco de Visser,,ZonMw
Drug Development Group,Phase 2 trials,Saco de Visser,,ZonMw
Drug Development Group,Phase 1 trials,Saco de Visser,,ZonMw
Drug Development Group,Phase 4 trials and Pharmacovigilance,Saco de Visser,,ZonMw
Drug Development Group,Clinical study design,Saco de Visser,,ZonMw
Communication and Project Management Group,Project communication and dissemination,Saco de Visser,,ZonMw
Communication and Project Management Group,Project management,Saco de Visser,,ZonMw
Drug Discovery Group,Pharmacodynamics (PD),Saco de Visser,,ZonMw
Drug Discovery Group,Pharmacokinetics (PK),Saco de Visser,,ZonMw
Drug Development Group,Clinical study report (CSR) creation,Keiko Ueda,https://orcid.org/0009-0009-5112-8972,The European Clinical Research Infrastructure Network (ECRIN)
Drug Development Group,Phase 3 trials,Keiko Ueda,https://orcid.org/0009-0009-5112-8972,The European Clinical Research Infrastructure Network (ECRIN)
Drug Development Group,Phase 2 trials,Keiko Ueda,https://orcid.org/0009-0009-5112-8972,The European Clinical Research Infrastructure Network (ECRIN)
Drug Development Group,Phase 1 trials,Keiko Ueda,https://orcid.org/0009-0009-5112-8972,The European Clinical Research Infrastructure Network (ECRIN)
Drug Development Group,Investigational new drug (IND) submission,Keiko Ueda,https://orcid.org/0009-0009-5112-8972,The European Clinical Research Infrastructure Network (ECRIN)
Drug Development Group,Clinical study design,Keiko Ueda,https://orcid.org/0009-0009-5112-8972,The European Clinical Research Infrastructure Network (ECRIN)
Drug Development Group,Medical writing,Keiko Ueda,https://orcid.org/0009-0009-5112-8972,The European Clinical Research Infrastructure Network (ECRIN)
Communication and Project Management Group,Project management,Keiko Ueda,https://orcid.org/0009-0009-5112-8972,The European Clinical Research Infrastructure Network (ECRIN)
Drug Development Group,Pre-clinical pharmacology,Tero Aittokallio,https://orcid.org/0000-0002-0886-9769,University of Helsinki (FIMM-UH)
Drug Development Group,Analytical Techniques,Tero Aittokallio,https://orcid.org/0000-0002-0886-9769,University of Helsinki (FIMM-UH)
Drug Development Group,Data management,Tero Aittokallio,https://orcid.org/0000-0002-0886-9769,University of Helsinki (FIMM-UH)
Communication and Project Management Group,Project communication and dissemination,Tero Aittokallio,https://orcid.org/0000-0002-0886-9769,University of Helsinki (FIMM-UH)
Drug Discovery Group,Target identification,Tero Aittokallio,https://orcid.org/0000-0002-0886-9769,University of Helsinki (FIMM-UH)
Drug Discovery Group,High-throughput screening (HTS),Tero Aittokallio,https://orcid.org/0000-0002-0886-9769,University of Helsinki (FIMM-UH)
Drug Discovery Group,Drug combinations,Tero Aittokallio,https://orcid.org/0000-0002-0886-9769,University of Helsinki (FIMM-UH)
Drug Development Group,Evidence synthesis,Zsuzsanna Petykó, https://orcid.org/0000-0002-9101-2546,Syreon Research Institute
Drug Development Group,Health technology assessment,Zsuzsanna Petykó, https://orcid.org/0000-0002-9101-2546,Syreon Research Institute
Drug Development Group,Health Economics,Zsuzsanna Petykó, https://orcid.org/0000-0002-9101-2546,Syreon Research Institute
Drug Development Group,Market access,Zsuzsanna Petykó, https://orcid.org/0000-0002-9101-2546,Syreon Research Institute
Drug Development Group,Clinical study design,Zsuzsanna Petykó, https://orcid.org/0000-0002-9101-2546,Syreon Research Institute
Drug Development Group,Medical writing,Zsuzsanna Petykó, https://orcid.org/0000-0002-9101-2546,Syreon Research Institute
Communication and Project Management Group,Project communication and dissemination,Zsuzsanna Petykó, https://orcid.org/0000-0002-9101-2546,Syreon Research Institute
Communication and Project Management Group,Project management,Zsuzsanna Petykó, https://orcid.org/0000-0002-9101-2546,Syreon Research Institute
Drug Development Group,Data management,Swapnil Potdar,https://orcid.org/0000-0002-2778-6918,University of Helsinki (FIMM-UH)
Drug Discovery Group,High-throughput screening (HTS),Swapnil Potdar,https://orcid.org/0000-0002-2778-6918,University of Helsinki (FIMM-UH)
Drug Development Group,Marketing authorization application (MAA),Peggy Beinlich,,Bfarm
Communication and Project Management Group,Project management,Peggy Beinlich,,Bfarm
Drug Development Group,Pre-clinical pharmacology,Claudia Fuchs,https://orcid.org/0009-0009-4788-9066,EURORDIS-Plateforme Maladies Rares
Drug Development Group,Phase 1 trials,Claudia Fuchs,https://orcid.org/0009-0009-4788-9066,EURORDIS-Plateforme Maladies Rares
Drug Development Group,Patient related documentation creation,Claudia Fuchs,https://orcid.org/0009-0009-4788-9066,EURORDIS-Plateforme Maladies Rares
Drug Development Group,Adaptive trial design,Claudia Fuchs,https://orcid.org/0009-0009-4788-9066,EURORDIS-Plateforme Maladies Rares
Drug Development Group,Medical writing,Claudia Fuchs,https://orcid.org/0009-0009-4788-9066,EURORDIS-Plateforme Maladies Rares
Communication and Project Management Group,Project communication and dissemination,Claudia Fuchs,https://orcid.org/0009-0009-4788-9066,EURORDIS-Plateforme Maladies Rares
Communication and Project Management Group,Project management,Claudia Fuchs,https://orcid.org/0009-0009-4788-9066,EURORDIS-Plateforme Maladies Rares
Drug Discovery Group,Drug delivery,Claudia Fuchs,https://orcid.org/0009-0009-4788-9066,EURORDIS-Plateforme Maladies Rares
Drug Discovery Group,Target identification,Claudia Fuchs,https://orcid.org/0009-0009-4788-9066,EURORDIS-Plateforme Maladies Rares
Drug Discovery Group,Biological discovery,Claudia Fuchs,https://orcid.org/0009-0009-4788-9066,EURORDIS-Plateforme Maladies Rares
Drug Discovery Group,Mechanism of action (MoA),Claudia Fuchs,https://orcid.org/0009-0009-4788-9066,EURORDIS-Plateforme Maladies Rares
Drug Discovery Group,Target validation,Claudia Fuchs,https://orcid.org/0009-0009-4788-9066,EURORDIS-Plateforme Maladies Rares
Drug Development Group,Evidence synthesis,Marcell Csanádi, https://orcid.org/0000-0002-5724-639X,Syreon Research Institute
Drug Development Group,Health technology assessment,Marcell Csanádi, https://orcid.org/0000-0002-5724-639X,Syreon Research Institute
Drug Development Group,Health Economics,Marcell Csanádi, https://orcid.org/0000-0002-5724-639X,Syreon Research Institute
Drug Development Group,Market access,Marcell Csanádi, https://orcid.org/0000-0002-5724-639X,Syreon Research Institute
Communication and Project Management Group,Project communication and dissemination,Marcell Csanádi, https://orcid.org/0000-0002-5724-639X,Syreon Research Institute
Drug Development Group,Market access,Anne Heß,,Bfarm
Drug Development Group,Pre-clinical pharmacology,Jeanette Reinshagen,https://orcid.org/0000-0002-8080-9170,Fraunhofer-Gesellschaft
Communication and Project Management Group,Project communication and dissemination,Jeanette Reinshagen,https://orcid.org/0000-0002-8080-9170,Fraunhofer-Gesellschaft
Drug Discovery Group,High-throughput screening (HTS),Jeanette Reinshagen,https://orcid.org/0000-0002-8080-9170,Fraunhofer-Gesellschaft
Drug Discovery Group,Hit confirmation | hit validation,Jeanette Reinshagen,https://orcid.org/0000-0002-8080-9170,Fraunhofer-Gesellschaft
Drug Development Group,Evidence synthesis,András Inotai, https://orcid.org/0000-0002-0663-2733,Syreon Research Institute
Drug Development Group,Health technology assessment,András Inotai, https://orcid.org/0000-0002-0663-2733,Syreon Research Institute
Drug Development Group,Health Economics,András Inotai, https://orcid.org/0000-0002-0663-2733,Syreon Research Institute
Drug Development Group,Market access,András Inotai, https://orcid.org/0000-0002-0663-2733,Syreon Research Institute
Communication and Project Management Group,Project management,András Inotai, https://orcid.org/0000-0002-0663-2733,Syreon Research Institute
Drug Development Group,Evidence synthesis,Heleen van der Meer, https://orcid.org/0000-0002-3329-3271,ZonMw
Drug Development Group,Phase 3 trials,Heleen van der Meer, https://orcid.org/0000-0002-3329-3271,ZonMw
Drug Development Group,Health technology assessment,Heleen van der Meer, https://orcid.org/0000-0002-3329-3271,ZonMw
Drug Development Group,Market access,Heleen van der Meer, https://orcid.org/0000-0002-3329-3271,ZonMw
Drug Development Group,Clinical statistics,Heleen van der Meer, https://orcid.org/0000-0002-3329-3271,ZonMw
Drug Development Group,Phase 4 trials and Pharmacovigilance,Heleen van der Meer, https://orcid.org/0000-0002-3329-3271,ZonMw
Drug Development Group,Clinical study design,Heleen van der Meer, https://orcid.org/0000-0002-3329-3271,ZonMw
Drug Development Group,Medical writing,Heleen van der Meer, https://orcid.org/0000-0002-3329-3271,ZonMw
Drug Development Group,Evidence synthesis,Dalma Hosszú,https://orcid.org/0009-0004-5835-2516,Syreon Research Institute
Drug Development Group,Health technology assessment,Dalma Hosszú,https://orcid.org/0009-0004-5835-2516,Syreon Research Institute
Drug Development Group,Health Economics,Dalma Hosszú,https://orcid.org/0009-0004-5835-2516,Syreon Research Institute
Drug Development Group,Market access,Dalma Hosszú,https://orcid.org/0009-0004-5835-2516,Syreon Research Institute
Communication and Project Management Group,Project communication and dissemination,Dalma Hosszú,https://orcid.org/0009-0004-5835-2516,Syreon Research Institute
Communication and Project Management Group,Project management,Dalma Hosszú,https://orcid.org/0009-0004-5835-2516,Syreon Research Institute
Communication and Project Management Group,Project management,Jani Saarela, https://orcid.org/0000-0001-7306-7175,University of Helsinki (FIMM-UH)
Drug Discovery Group,High-throughput screening (HTS),Jani Saarela, https://orcid.org/0000-0001-7306-7175,University of Helsinki (FIMM-UH)
Drug Discovery Group,Drug combinations,Jani Saarela, https://orcid.org/0000-0001-7306-7175,University of Helsinki (FIMM-UH)
Drug Development Group,Evidence synthesis,Zoltán Kaló, https://orcid.org/0000-0001-7762-2607,Syreon Research Institute
Drug Development Group,Phase 3 trials,Zoltán Kaló, https://orcid.org/0000-0001-7762-2607,Syreon Research Institute
Drug Development Group,Health technology assessment,Zoltán Kaló, https://orcid.org/0000-0001-7762-2607,Syreon Research Institute
Drug Development Group,Health Economics,Zoltán Kaló, https://orcid.org/0000-0001-7762-2607,Syreon Research Institute
Drug Development Group,Market access,Zoltán Kaló, https://orcid.org/0000-0001-7762-2607,Syreon Research Institute
Drug Development Group,Phase 4 trials and Pharmacovigilance,Zoltán Kaló, https://orcid.org/0000-0001-7762-2607,Syreon Research Institute
Drug Development Group,Clinical study design,Zoltán Kaló, https://orcid.org/0000-0001-7762-2607,Syreon Research Institute
Drug Development Group,Medical writing,Zoltán Kaló, https://orcid.org/0000-0001-7762-2607,Syreon Research Institute
Drug Development Group,Pre-clinical pharmacology,Marianna Tampere, https://orcid.org/0000-0001-5744-3206,Karolinska Institutet
Communication and Project Management Group,Project communication and dissemination,Marianna Tampere, https://orcid.org/0000-0001-5744-3206,Karolinska Institutet
Communication and Project Management Group,Project management,Marianna Tampere, https://orcid.org/0000-0001-5744-3206,Karolinska Institutet
Drug Discovery Group,High-throughput screening (HTS),Marianna Tampere, https://orcid.org/0000-0001-5744-3206,Karolinska Institutet
Drug Discovery Group,Mechanism of action (MoA),Marianna Tampere, https://orcid.org/0000-0001-5744-3206,Karolinska Institutet
Drug Discovery Group,Hit confirmation | hit validation,Marianna Tampere, https://orcid.org/0000-0001-5744-3206,Karolinska Institutet
Drug Development Group,Pre-clinical pharmacology,Francesca Bruzzese,https://orcid.org/0000-0001-7741-9086,Istituto Nazionale Tumori
Drug Development Group,Clinical study design,Francesca Bruzzese,https://orcid.org/0000-0001-7741-9086,Istituto Nazionale Tumori
Communication and Project Management Group,Project communication and dissemination,Francesca Bruzzese,https://orcid.org/0000-0001-7741-9086,Istituto Nazionale Tumori
Drug Discovery Group,Biological discovery,Francesca Bruzzese,https://orcid.org/0000-0001-7741-9086,Istituto Nazionale Tumori
Drug Discovery Group,High-throughput screening (HTS),Francesca Bruzzese,https://orcid.org/0000-0001-7741-9086,Istituto Nazionale Tumori
Drug Discovery Group,Mechanism of action (MoA),Francesca Bruzzese,https://orcid.org/0000-0001-7741-9086,Istituto Nazionale Tumori
Drug Discovery Group,Drug combinations,Francesca Bruzzese,https://orcid.org/0000-0001-7741-9086,Istituto Nazionale Tumori
Drug Discovery Group,In-vivo efficacy evaluation,Francesca Bruzzese,https://orcid.org/0000-0001-7741-9086,Istituto Nazionale Tumori
Drug Development Group,Pre-clinical pharmacology,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Drug Development Group,Phase 3 trials,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Drug Development Group,Phase 2 trials,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Drug Development Group,Marketing authorization application (MAA),Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Drug Development Group,Phase 1 trials,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Drug Development Group,Investigational new drug (IND) submission,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Drug Development Group,Phase 4 trials and Pharmacovigilance,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Communication and Project Management Group,Project communication and dissemination,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Communication and Project Management Group,Ethics and ELSI,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Communication and Project Management Group,Project management,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Communication and Project Management Group,Legal expertise,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Drug Discovery Group,Target identification,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Drug Discovery Group,In-vivo modelling,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Drug Discovery Group,Hit-to-lead (HTL) | lead generation,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Drug Discovery Group,Hit confirmation | hit validation,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Drug Discovery Group,Target validation,Carmine Talarico,https://orcid.org/0000-0003-4789-0955,Dompe Farmaceutici-SpA
Drug Development Group,Pre-clinical pharmacology,Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Drug Development Group,Phase 3 trials,Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Drug Development Group,Active pharmaceutical ingredient (API) manufacturing,Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Drug Development Group,Phase 2 trials,Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Drug Development Group,Marketing authorization application (MAA),Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Drug Development Group,Phase 1 trials,Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Drug Development Group,Investigational new drug (IND) submission,Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Drug Development Group,Phase 4 trials and Pharmacovigilance,Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Communication and Project Management Group,Project management,Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Communication and Project Management Group,Legal expertise,Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Drug Discovery Group,Medicinal chemistry,Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Drug Discovery Group,Natural products,Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Drug Discovery Group,Hit-to-lead (HTL) | lead generation,Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Drug Discovery Group,Mechanism of action (MoA),Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Drug Discovery Group,Hit confirmation | hit validation,Andrea Beccari,https://orcid.org/0000-0001-6830-2695,Dompe Farmaceutici-SpA
Communication and Project Management Group,Project management,Davide Graziani, https://orcid.org/0000-0003-1826-5392,Dompe Farmaceutici-SpA
Drug Discovery Group,Medicinal chemistry,Davide Graziani, https://orcid.org/0000-0003-1826-5392,Dompe Farmaceutici-SpA
Drug Discovery Group,Pharmacokinetics (PK),Davide Graziani, https://orcid.org/0000-0003-1826-5392,Dompe Farmaceutici-SpA
Drug Discovery Group,High-throughput screening (HTS),Davide Graziani, https://orcid.org/0000-0003-1826-5392,Dompe Farmaceutici-SpA
Drug Discovery Group,Hit-to-lead (HTL) | lead generation,Davide Graziani, https://orcid.org/0000-0003-1826-5392,Dompe Farmaceutici-SpA
Drug Discovery Group,In-vitro toxicity testing - Ames,Davide Graziani, https://orcid.org/0000-0003-1826-5392,Dompe Farmaceutici-SpA
Drug Discovery Group,Hit confirmation | hit validation,Davide Graziani, https://orcid.org/0000-0003-1826-5392,Dompe Farmaceutici-SpA
Drug Discovery Group,Pro-drugs,Davide Graziani, https://orcid.org/0000-0003-1826-5392,Dompe Farmaceutici-SpA
Drug Discovery Group,Absorption distribution metabolism elimination (ADME),Davide Graziani, https://orcid.org/0000-0003-1826-5392,Dompe Farmaceutici-SpA
Drug Development Group,Data management,Jordi Quintana, https://orcid.org/0000-0002-7059-7418,Chemotargets
Communication and Project Management Group,Project management,Jordi Quintana, https://orcid.org/0000-0002-7059-7418,Chemotargets
Drug Discovery Group,Medicinal chemistry,Jordi Quintana, https://orcid.org/0000-0002-7059-7418,Chemotargets
Drug Discovery Group,Target identification,Jordi Quintana, https://orcid.org/0000-0002-7059-7418,Chemotargets
Drug Discovery Group,Hit-to-lead (HTL) | lead generation,Jordi Quintana, https://orcid.org/0000-0002-7059-7418,Chemotargets
Drug Discovery Group,Mechanism of action (MoA),Jordi Quintana, https://orcid.org/0000-0002-7059-7418,Chemotargets
Drug Discovery Group,Hit confirmation | hit validation,Jordi Quintana, https://orcid.org/0000-0002-7059-7418,Chemotargets
Drug Development Group,Clinical statistics,Martin Hofmann-Apitius,https://orcid.org/0000-0001-9012-6720,Fraunhofer-Gesellschaft
Drug Development Group,Data management,Martin Hofmann-Apitius,https://orcid.org/0000-0001-9012-6720,Fraunhofer-Gesellschaft
Communication and Project Management Group,Project communication and dissemination,Martin Hofmann-Apitius,https://orcid.org/0000-0001-9012-6720,Fraunhofer-Gesellschaft
Communication and Project Management Group,Project management,Martin Hofmann-Apitius,https://orcid.org/0000-0001-9012-6720,Fraunhofer-Gesellschaft
Drug Discovery Group,Target identification,Martin Hofmann-Apitius,https://orcid.org/0000-0001-9012-6720,Fraunhofer-Gesellschaft
Drug Discovery Group,Biological discovery,Martin Hofmann-Apitius,https://orcid.org/0000-0001-9012-6720,Fraunhofer-Gesellschaft
Drug Development Group,Pre-clinical pharmacology,Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Drug Development Group,Clinical study design,Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Communication and Project Management Group,Project management,Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Drug Discovery Group,Pharmacodynamics (PD),Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Drug Discovery Group,Pharmacokinetics (PK),Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Drug Discovery Group,Target identification,Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Drug Discovery Group,Biological discovery,Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Drug Discovery Group,High-throughput screening (HTS),Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Drug Discovery Group,Hit-to-lead (HTL) | lead generation,Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Drug Discovery Group,Mechanism of action (MoA),Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Drug Discovery Group,Hit confirmation | hit validation,Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Drug Discovery Group,In-vivo efficacy evaluation,Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Drug Discovery Group,Absorption distribution metabolism elimination (ADME),Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Drug Discovery Group,Target validation,Aimo Kannt,https://orcid.org/0000-0002-5197-2286,Fraunhofer-Gesellschaft
Drug Development Group,Investigational new drug (IND) submission,Rok Dreu,https://orcid.org/0000-0002-5722-6022,Ljubljana University
Communication and Project Management Group,Project management,Rok Dreu,https://orcid.org/0000-0002-5722-6022,Ljubljana University
Drug Discovery Group,Drug delivery,Rok Dreu,https://orcid.org/0000-0002-5722-6022,Ljubljana University
Drug Discovery Group,Drug Formulation,Rok Dreu,https://orcid.org/0000-0002-5722-6022,Ljubljana University
Communication and Project Management Group,Project management,Annika Jenmalm Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,Medicinal chemistry,Annika Jenmalm Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,Target identification,Annika Jenmalm Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,High-throughput screening (HTS),Annika Jenmalm Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,Hit-to-lead (HTL) | lead generation,Annika Jenmalm Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,Mechanism of action (MoA),Annika Jenmalm Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,Hit confirmation | hit validation,Annika Jenmalm Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,Absorption distribution metabolism elimination (ADME),Annika Jenmalm Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,Target validation,Annika Jenmalm Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Development Group,Adaptive trial design,Päivi Östling, https://orcid.org/0000-0001-5501-466X,Karolinska Institutet
Communication and Project Management Group,Project management,Päivi Östling, https://orcid.org/0000-0001-5501-466X,Karolinska Institutet
Drug Discovery Group,High-throughput screening (HTS),Päivi Östling, https://orcid.org/0000-0001-5501-466X,Karolinska Institutet
Drug Discovery Group,Pharmacokinetics (PK),Igor Locatelli, https://orcid.org/0000-0002-0052-8986,Ljubljana University
Drug Development Group,Pre-clinical pharmacology,Maddalena Fratelli,https://orcid.org/0000-0002-1769-3427,Mario Negri Institute for Pharmacological Research
Drug Development Group,Health technology assessment,Maddalena Fratelli,https://orcid.org/0000-0002-1769-3427,Mario Negri Institute for Pharmacological Research
Drug Development Group,Analytical Techniques,Maddalena Fratelli,https://orcid.org/0000-0002-1769-3427,Mario Negri Institute for Pharmacological Research
Communication and Project Management Group,Project communication and dissemination,Maddalena Fratelli,https://orcid.org/0000-0002-1769-3427,Mario Negri Institute for Pharmacological Research
Drug Discovery Group,Pharmacodynamics (PD),Maddalena Fratelli,https://orcid.org/0000-0002-1769-3427,Mario Negri Institute for Pharmacological Research
Drug Discovery Group,Pharmacokinetics (PK),Maddalena Fratelli,https://orcid.org/0000-0002-1769-3427,Mario Negri Institute for Pharmacological Research
Drug Discovery Group,Biological discovery,Maddalena Fratelli,https://orcid.org/0000-0002-1769-3427,Mario Negri Institute for Pharmacological Research
Drug Discovery Group,Mechanism of action (MoA),Maddalena Fratelli,https://orcid.org/0000-0002-1769-3427,Mario Negri Institute for Pharmacological Research
Drug Discovery Group,Drug combinations,Maddalena Fratelli,https://orcid.org/0000-0002-1769-3427,Mario Negri Institute for Pharmacological Research
Drug Discovery Group,Absorption distribution metabolism elimination (ADME),Maddalena Fratelli,https://orcid.org/0000-0002-1769-3427,Mario Negri Institute for Pharmacological Research
Drug Discovery Group,Absorption distribution metabolism elimination (ADME),Simon Žakelj,https://orcid.org/0000-0002-4967-7114,Ljubljana University
Drug Discovery Group,Medicinal chemistry,Flavio Ballante,https://orcid.org/0000-0002-4831-3423,Karolinska Institutet
Drug Discovery Group,Target identification,Flavio Ballante,https://orcid.org/0000-0002-4831-3423,Karolinska Institutet
Drug Discovery Group,Hit-to-lead (HTL) | lead generation,Flavio Ballante,https://orcid.org/0000-0002-4831-3423,Karolinska Institutet
Drug Discovery Group,Mechanism of action (MoA),Flavio Ballante,https://orcid.org/0000-0002-4831-3423,Karolinska Institutet
Drug Development Group,Active pharmaceutical ingredient (API) manufacturing,Alicia Soler Cantón,https://orcid.org/0009-0003-5742-4971,EATRIS
Drug Development Group,Analytical Techniques,Alicia Soler Cantón,https://orcid.org/0009-0003-5742-4971,EATRIS
Drug Development Group,Marketing authorization application (MAA),Alicia Soler Cantón,https://orcid.org/0009-0003-5742-4971,EATRIS
Drug Development Group,Investigational new drug (IND) submission,Alicia Soler Cantón,https://orcid.org/0009-0003-5742-4971,EATRIS
Drug Development Group,Patient related documentation creation,Alicia Soler Cantón,https://orcid.org/0009-0003-5742-4971,EATRIS
Communication and Project Management Group,Project communication and dissemination,Alicia Soler Cantón,https://orcid.org/0009-0003-5742-4971,EATRIS
Communication and Project Management Group,Project management,Alicia Soler Cantón,https://orcid.org/0009-0003-5742-4971,EATRIS
Drug Discovery Group,Drug delivery,Alicia Soler Cantón,https://orcid.org/0009-0003-5742-4971,EATRIS
Drug Discovery Group,Drug Formulation,Alicia Soler Cantón,https://orcid.org/0009-0003-5742-4971,EATRIS
Drug Discovery Group,Biological discovery,Alicia Soler Cantón,https://orcid.org/0009-0003-5742-4971,EATRIS
Drug Development Group,Data management,Marc Jacobs,https://orcid.org/0000-0003-4153-3930,Fraunhofer-Gesellschaft
Communication and Project Management Group,Project management,Marc Jacobs,https://orcid.org/0000-0003-4153-3930,Fraunhofer-Gesellschaft
Drug Discovery Group,High-throughput screening (HTS),Marc Jacobs,https://orcid.org/0000-0003-4153-3930,Fraunhofer-Gesellschaft
Drug Discovery Group,Mechanism of action (MoA),Marc Jacobs,https://orcid.org/0000-0003-4153-3930,Fraunhofer-Gesellschaft
Drug Development Group,Patient related documentation creation,Pan Pantziarka,https://orcid.org/0000-0002-4676-7835,Anti-cancer fund
Drug Development Group,Medical writing,Pan Pantziarka,https://orcid.org/0000-0002-4676-7835,Anti-cancer fund
Communication and Project Management Group,Project communication and dissemination,Pan Pantziarka,https://orcid.org/0000-0002-4676-7835,Anti-cancer fund
Drug Discovery Group,Target identification,Pan Pantziarka,https://orcid.org/0000-0002-4676-7835,Anti-cancer fund
Drug Development Group,Phase 3 trials,Alessandra Leone, https://orcid.org/0000-0002-1051-2937,Istituto Nazionale Tumori
Drug Development Group,Phase 2 trials,Alessandra Leone, https://orcid.org/0000-0002-1051-2937,Istituto Nazionale Tumori
Drug Development Group,Phase 1 trials,Alessandra Leone, https://orcid.org/0000-0002-1051-2937,Istituto Nazionale Tumori
Drug Development Group,Clinical study design,Alessandra Leone, https://orcid.org/0000-0002-1051-2937,Istituto Nazionale Tumori
Communication and Project Management Group,Project management,Alessandra Leone, https://orcid.org/0000-0002-1051-2937,Istituto Nazionale Tumori
Drug Discovery Group,High-throughput screening (HTS),Alessandra Leone, https://orcid.org/0000-0002-1051-2937,Istituto Nazionale Tumori
Drug Discovery Group,Mechanism of action (MoA),Alessandra Leone, https://orcid.org/0000-0002-1051-2937,Istituto Nazionale Tumori
Drug Discovery Group,Drug combinations,Alessandra Leone, https://orcid.org/0000-0002-1051-2937,Istituto Nazionale Tumori
Drug Discovery Group,Target validation,Alessandra Leone, https://orcid.org/0000-0002-1051-2937,Istituto Nazionale Tumori
Communication and Project Management Group,Project management,Annika Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,Medicinal chemistry,Annika Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,Target identification,Annika Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,High-throughput screening (HTS),Annika Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,Hit-to-lead (HTL) | lead generation,Annika Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,Mechanism of action (MoA),Annika Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,Hit confirmation | hit validation,Annika Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Drug Discovery Group,Target validation,Annika Jensen, https://orcid.org/0000-0002-6053-8457,Karolinska Institutet
Communication and Project Management Group,Project communication and dissemination,Katja Herzog,https://orcid.org/0000-0002-1389-8118,Fraunhofer-Gesellschaft
Communication and Project Management Group,Project management,Katja Herzog,https://orcid.org/0000-0002-1389-8118,Fraunhofer-Gesellschaft
Drug Discovery Group,Biological discovery,Katja Herzog,https://orcid.org/0000-0002-1389-8118,Fraunhofer-Gesellschaft
Communication and Project Management Group,Project communication and dissemination,Anna-Lena Gustavsson, https://orcid.org/0000-0003-4332-2336,Karolinska Institutet
Communication and Project Management Group,Project management,Anna-Lena Gustavsson, https://orcid.org/0000-0003-4332-2336,Karolinska Institutet
Drug Discovery Group,Medicinal chemistry,Anna-Lena Gustavsson, https://orcid.org/0000-0003-4332-2336,Karolinska Institutet
Drug Discovery Group,Target identification,Anna-Lena Gustavsson, https://orcid.org/0000-0003-4332-2336,Karolinska Institutet
Drug Discovery Group,Biological discovery,Anna-Lena Gustavsson, https://orcid.org/0000-0003-4332-2336,Karolinska Institutet
Drug Discovery Group,High-throughput screening (HTS),Anna-Lena Gustavsson, https://orcid.org/0000-0003-4332-2336,Karolinska Institutet
Drug Discovery Group,Hit-to-lead (HTL) | lead generation,Anna-Lena Gustavsson, https://orcid.org/0000-0003-4332-2336,Karolinska Institutet
Drug Discovery Group,Mechanism of action (MoA),Anna-Lena Gustavsson, https://orcid.org/0000-0003-4332-2336,Karolinska Institutet
Drug Discovery Group,Hit confirmation | hit validation,Anna-Lena Gustavsson, https://orcid.org/0000-0003-4332-2336,Karolinska Institutet
Drug Discovery Group,Target validation,Anna-Lena Gustavsson, https://orcid.org/0000-0003-4332-2336,Karolinska Institutet
Drug Development Group,Pre-clinical pharmacology,Judith Palou,,Teamit Research
Drug Development Group,Clinical study report (CSR) creation,Judith Palou,,Teamit Research
Drug Development Group,Phase 3 trials,Judith Palou,,Teamit Research
Drug Development Group,Phase 2 trials,Judith Palou,,Teamit Research
Drug Development Group,Analytical Techniques,Judith Palou,,Teamit Research
Drug Development Group,Market access,Judith Palou,,Teamit Research
Drug Development Group,Phase 1 trials,Judith Palou,,Teamit Research
Drug Development Group,Phase 4 trials and Pharmacovigilance,Judith Palou,,Teamit Research
Drug Development Group,Quality assurance (clinical trials),Judith Palou,,Teamit Research
Communication and Project Management Group,Project communication and dissemination,Judith Palou,,Teamit Research
Communication and Project Management Group,Project management,Judith Palou,,Teamit Research
Drug Discovery Group,Medicinal chemistry,Judith Palou,,Teamit Research
Drug Discovery Group,Pharmacodynamics (PD),Judith Palou,,Teamit Research
Drug Discovery Group,Pharmacokinetics (PK),Judith Palou,,Teamit Research
Drug Discovery Group,Drug delivery,Judith Palou,,Teamit Research
Drug Discovery Group,Target identification,Judith Palou,,Teamit Research
Drug Discovery Group,Drug Formulation,Judith Palou,,Teamit Research
Drug Discovery Group,Mechanism of action (MoA),Judith Palou,,Teamit Research
Drug Discovery Group,Drug combinations,Judith Palou,,Teamit Research
Drug Discovery Group,Pro-drugs,Judith Palou,,Teamit Research
Communication and Project Management Group,Project communication and dissemination,Berta Gumí Audenis, https://orcid.org/0000-0002-8917-0553,Teamit Research
Communication and Project Management Group,Project management,Berta Gumí Audenis, https://orcid.org/0000-0002-8917-0553,Teamit Research
Communication and Project Management Group,Project management,Martina Spadetto,,Teamit Research
Drug Development Group,Clinical statistics,Sofia Sintoris,,Teamit Research
Communication and Project Management Group,Project communication and dissemination,Sofia Sintoris,,Teamit Research
Drug Discovery Group,Biological discovery,Sofia Sintoris,,Teamit Research
Communication and Project Management Group,Project communication and dissemination,Federica Righi,,Teamit Research
Communication and Project Management Group,Project management,Federica Righi,,Teamit Research
Communication and Project Management Group,Project communication and dissemination,Gisela Pairó,,Teamit Research
Communication and Project Management Group,Project communication and dissemination,Ivette Corominas,,Teamit Research
Drug Development Group,Pre-clinical pharmacology,Sarai Rodríguez Navarro,https://orcid.org/0000-0002-7489-4532,Teamit Research
Drug Development Group,Patient related documentation creation,Sarai Rodríguez Navarro,https://orcid.org/0000-0002-7489-4532,Teamit Research
Drug Development Group,Medical writing,Sarai Rodríguez Navarro,https://orcid.org/0000-0002-7489-4532,Teamit Research
Communication and Project Management Group,Project communication and dissemination,Sarai Rodríguez Navarro,https://orcid.org/0000-0002-7489-4532,Teamit Research
Communication and Project Management Group,Project management,Sarai Rodríguez Navarro,https://orcid.org/0000-0002-7489-4532,Teamit Research
Drug Discovery Group,In-vivo modelling,Sarai Rodríguez Navarro,https://orcid.org/0000-0002-7489-4532,Teamit Research
Drug Discovery Group,Drug combinations,Sarai Rodríguez Navarro,https://orcid.org/0000-0002-7489-4532,Teamit Research
Drug Discovery Group,In-vivo efficacy evaluation,Sarai Rodríguez Navarro,https://orcid.org/0000-0002-7489-4532,Teamit Research
